Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 3Not yet recruiting 3Recruiting 2Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Colorectal Neoplasms 3Skin Neoplasms 2Melanoma 2Esophageal Neoplasms 2Carcinoma, Hepatocellular 2Urologic Neoplasms 1Urologic Diseases 1Urinary Bladder Neoplasms 1Urinary Bladder Diseases 1Turcot syndrome 1Solid Tumors 1Solid Tumor, Adult 1Rectal Neoplasms 1Radiation Pneumonitis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Non-small Cell Lung Cancer Metastatic 1Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1NSCLC 1Motor Activity 1Lung Neoplasms 1Locally Advanced Esophageal Squamous Cell Carcinoma 1Kidney Neoplasms 1Head and Neck Neoplasms 1Glioblastoma 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1

Interventions

Paclitaxel 8Radiotherapy 7Cisplatin 6pembrolizumab 4Fluorouracil 4Surgical Procedures, Operative 3Radiation 3Oxaliplatin 3Levoleucovorin 3Leucovorin 3Esophagectomy 3Drug Therapy 3Carboplatin 3lenvatinib 2durvalumab 2Taxes 2TP protocol 2Radiotherapy, Intensity-Modulated 2Nivolumab 2Neoadjuvant Therapy 2Irinotecan 2Capecitabine 2trifluridine tipiracil drug combination 1tislelizumab 1palbociclib 1osimertinib 1obinutuzumab 1nedaplatin 1naptumomab estafenatox 1futibatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Esophageal Squamous Cell Carcinoma × Immune Checkpoint Inhibitors × Clear all
NCT07339488 2026-01-14

ILDR-03

Shantou University Medical College

Phase 2 Active not recruiting
43 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡